These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 23724146

  • 1. Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.
    Savić R, He X, Fiel I, Schuchman EH.
    PLoS One; 2013; 8(5):e65620. PubMed ID: 23724146
    [Abstract] [Full Text] [Related]

  • 2. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B, Wei W, Ma L, Yang B, Gill RM, Chua MS, Butte AJ, So S.
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [Abstract] [Full Text] [Related]

  • 3. Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo.
    Kusano H, Ogasawara S, Akiba J, Nakayama M, Ueda K, Yano H.
    Int J Oncol; 2013 Jun; 42(6):1897-903. PubMed ID: 23588838
    [Abstract] [Full Text] [Related]

  • 4. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI, Tai WT, Hung MH, Tsai MH, Chen MH, Chang MJ, Shiau CW, Chen KF.
    Cancer Lett; 2016 Feb 28; 371(2):205-13. PubMed ID: 26679051
    [Abstract] [Full Text] [Related]

  • 5. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM.
    Gastroenterology; 2016 Dec 28; 151(6):1192-1205. PubMed ID: 27614046
    [Abstract] [Full Text] [Related]

  • 6. Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
    Kuczynski EA, Yin M, Bar-Zion A, Lee CR, Butz H, Man S, Daley F, Vermeulen PB, Yousef GM, Foster FS, Reynolds AR, Kerbel RS.
    J Natl Cancer Inst; 2016 Aug 28; 108(8):. PubMed ID: 27059374
    [Abstract] [Full Text] [Related]

  • 7. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H, Zhang C, Chi H, Meng Z.
    Int J Oncol; 2018 Jun 28; 52(6):2051-2060. PubMed ID: 29620259
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH, Cheng AL.
    Cancer Lett; 2016 Oct 10; 381(1):58-66. PubMed ID: 27431312
    [Abstract] [Full Text] [Related]

  • 9. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M, Chen C, Geng J, Han D, Wang T, Xie T, Wang L, Wang Y, Wang C, Lei Z, Chu X.
    Cancer Lett; 2017 Jul 10; 398():12-21. PubMed ID: 28377178
    [Abstract] [Full Text] [Related]

  • 10. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
    Chen JC, Chuang HY, Hsu FT, Chen YC, Chien YC, Hwang JJ.
    Oncotarget; 2016 Dec 20; 7(51):85450-85463. PubMed ID: 27863427
    [Abstract] [Full Text] [Related]

  • 12. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L.
    Hepatology; 2013 May 20; 57(5):1847-57. PubMed ID: 23299930
    [Abstract] [Full Text] [Related]

  • 13. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T.
    J Hematol Oncol; 2016 Mar 08; 9():20. PubMed ID: 26957312
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
    Alsaied OA, Sangwan V, Banerjee S, Krosch TC, Chugh R, Saluja A, Vickers SM, Jensen EH.
    Surgery; 2014 Aug 08; 156(2):270-9. PubMed ID: 24953273
    [Abstract] [Full Text] [Related]

  • 15. Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model.
    Qiu YQ, Zhou J, Kang XS, Ding LM, Yu W, Tan FL, Deng DF.
    Sci Rep; 2014 Mar 17; 4():4324. PubMed ID: 24632756
    [Abstract] [Full Text] [Related]

  • 16. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, Liu S, Zhang Y.
    PLoS One; 2014 Mar 17; 9(12):e115565. PubMed ID: 25531114
    [Abstract] [Full Text] [Related]

  • 17. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 17; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 18. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang X, Li J, Qiao H, Ni S, Sun X.
    Cancer Lett; 2014 Dec 01; 355(1):96-105. PubMed ID: 25218350
    [Abstract] [Full Text] [Related]

  • 19. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
    Chen CH, Chen MC, Wang JC, Tsai AC, Chen CS, Liou JP, Pan SL, Teng CM.
    Clin Cancer Res; 2014 Mar 01; 20(5):1274-1287. PubMed ID: 24520095
    [Abstract] [Full Text] [Related]

  • 20. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M, Fei Z, Zhang G.
    Biomed Pharmacother; 2018 Jan 01; 97():1282-1288. PubMed ID: 29156516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.